Need Help?

Study of renal cancers and renal cancer metastases

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00010001001 Illumina 450K 62
EGAD00010001564 Affymetrix GeneChip miRNA 4.0 56
EGAD00010001589 Affymetrix Human Transcriptome Array 2.0 112
EGAD00010002323 GeneChip HTA 2.0 53
EGAD00010002352 GeneChip HTA 2.0 124
EGAD00010002353 GeneChip HTA 2.0 306
EGAD00010002392 GeneChip HTA 2.0 24
Publications Citations
Methylomes of renal cell lines and tumors or metastases differ significantly with impact on pharmacogenes.
Sci Rep 6: 2016 29930
Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.
Eur Urol Focus 5: 2019 608-618
Clinical utility of the S3-score for molecular prediction of outcome in non-metastatic and metastatic clear cell renal cell carcinoma.
BMC Med 16: 2018 108
Characterization of the breast cancer resistance protein (BCRP/ABCG2) in clear cell renal cell carcinoma.
Int J Cancer 143: 2018 3181-3193
Hypertonicity-Affected Genes Are Differentially Expressed in Clear Cell Renal Cell Carcinoma and Correlate with Cancer-Specific Survival.
Cancers (Basel) 12: 2019 E6
Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy.
Genome Med 12: 2020 32
Nicotinamide-N-methyltransferase is a promising metabolic drug target for primary and metastatic clear cell renal cell carcinoma.
Clin Transl Med 12: 2022 e883
A Molecularly Characterized Preclinical Platform of Subcutaneous Renal Cell Carcinoma (RCC) Patient-Derived Xenograft Models to Evaluate Novel Treatment Strategies.
Front Oncol 12: 2022 889789
A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy.
Genome Med 14: 2022 105